Syringe

Second death by overdose at Mountain Institution: once again, CSC fails the community

Retrieved on: 
Thursday, November 2, 2023
CSC, Cell, Mountain Institution, Union, Rehabilitation, Correctional Service of Canada, Drug, Corrections, Nebraska Department of Correctional Services, Safety, Needle, Syringe, Correction Officers' Benevolent Association, United States drug overdose death rates and totals over time, Nursing

AGASSIZ, BC, Nov. 2, 2023 /CNW/ - A second overdose death in seven days has occurred at Mountain Institution on Nov 1, 2023.

Key Points: 
  • AGASSIZ, BC, Nov. 2, 2023 /CNW/ - A second overdose death in seven days has occurred at Mountain Institution on Nov 1, 2023.
  • First aid was administered but the inmate was pronounced dead by paramedics at 0730.
  • This second overdose at Mountain highlights the ineffectiveness of the PNEP program and shows that CSC has no intention of releasing inmates drug-free to the community.
  • Neither a solution to the opioid crisis nor a safe access to syringes, PNEP will only add to the death toll.

ClorDiSys Expands Chlorine Dioxide Gas Medical Device Sterilization into Europe

Retrieved on: 
Monday, October 30, 2023
Universe, Temperature, Medical device, United States Environmental Protection Agency, Conference, Chlorine, Disinfectant, Multimedia, Ethylene oxide, PDA, EPA, Syringe, Johnson & Johnson, Safety, Sterilization, Sewage treatment

BRANCHBURG, N.J., Oct. 30, 2023 /PRNewswire/ -- ClorDiSys Solutions, Inc., headquartered in Branchburg, NJ, officially expands its presence in Europe for its chlorine dioxide gas technology for Medical Device sterilization at the PDA Universe of Pre-filled Syringes and Injection Devices Conference in Gothenburg, Sweden.

Key Points: 
  • BRANCHBURG, N.J., Oct. 30, 2023 /PRNewswire/ -- ClorDiSys Solutions, Inc., headquartered in Branchburg, NJ, officially expands its presence in Europe for its chlorine dioxide gas technology for Medical Device sterilization at the PDA Universe of Pre-filled Syringes and Injection Devices Conference in Gothenburg, Sweden.
  • ClorDiSys' chlorine dioxide gas is non-carcinogenic, non-explosive, and is a United States Environmental Protection Agency (EPA) registered sterilant.
  • Chlorine dioxide vacuum pressure sterilizers allow for the option of the sterilization of complex designed devices within bulk packaging, as well as a vast reduction in cycle time and complexity of the chlorine dioxide gas sterilization process.
  • ClorDiSys developed its technology through Johnson and Johnson, and chlorine dioxide gas has been providing true sterilization for medical devices for over 25 years.

Safety Concerns in Med Spas with Little to No Physician Involvement

Retrieved on: 
Thursday, October 19, 2023
Syringe, Public Perception of Salvador Allende, Day, Physician, Dermatology, MD, Society, Patient, Patient safety, Nursing, Advertising

The findings emphasize the patient safety risks medical spas may currently pose and highlight the need for public protection measures, such as the American Society for Dermatologic Surgery Association’s (ASDSA) “ Medical Spa Safety Act ” to ensure patient safety and proper oversight of care in medical spas.

Key Points: 
  • The findings emphasize the patient safety risks medical spas may currently pose and highlight the need for public protection measures, such as the American Society for Dermatologic Surgery Association’s (ASDSA) “ Medical Spa Safety Act ” to ensure patient safety and proper oversight of care in medical spas.
    "
  • A Survey of Truth in Advertising Among Medical Spas ” surveyed 127 medical spas in the Chicago area and revealed that non-physicians perform most cosmetic medical procedures at medical spas often without patients’ knowledge of the significant variation in medical supervision and training.
  • This also means there is little to no medical evaluation and management by a physician at medical spas.
  • This study illustrates medical spa safety concerns expressed by the public and the correlation between less physician involvement and higher complication rates of certain cosmetic medical procedures.

Pre-Sterilized/Ready to Use Pharmaceutical Packaging Market, 2035 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 24, 2023
Health, Pharmaceutical, Type, Elastomer, FDA, Biomedical Advanced Research and Development Authority, AptarGroup, Vaccine, Container, SCHOTT, Dätwyler, West Pharmaceutical Services, Glass, BARDA, Development, Growth, COVID-19, RTU, Duran (glass), EMA, Porta Nuova (Milan), Safety, Material, EZ, Investment, Syringe, Value proposition, Patient safety, Sterilization, Medical device, Fine chemical, Borosilicate glass, Stevanato Group

This focus on product safety has given rise to the adoption of pre-sterilized or ready-to-use containers and closures in pharmaceutical packaging.

Key Points: 
  • This focus on product safety has given rise to the adoption of pre-sterilized or ready-to-use containers and closures in pharmaceutical packaging.
  • It's essential to highlight that the growing demand for secure drug delivery systems has fueled the expansion of the global pharmaceutical packaging market.
  • The integration of ready-to-use (RTU) packaging containers in the pharmaceutical sector enables expedited product launches through an optimized value chain.
  • The current landscape of pre-sterilized / ready to use pharmaceutical primary packaging features close to 95 RTU containers and 85 RTU closures.

Next generation pharma glass: SCHOTT AG launches FIOLAX® Pro glass tubing

Retrieved on: 
Tuesday, October 24, 2023
Packaging, Medical Supplies, Health, Manufacturing, Other Manufacturing, Pharmaceutical, Carbon, Astronomy, Science, Health care, SCHOTT, Glass, Pro, Multimedia, German, Federal Ministry of Science, Technology and Innovation, Economy, PCF, Carl-Zeiss-Stiftung, Syringe, Consumer electronics, DNA, Borosilicate glass, Automotive industry

With its borosilicate glass being the gold standard for storing lifesaving medications for more than a century, the company is now taking the next steps by introducing improved glass tubing to the global pharma market.

Key Points: 
  • With its borosilicate glass being the gold standard for storing lifesaving medications for more than a century, the company is now taking the next steps by introducing improved glass tubing to the global pharma market.
  • View the full release here: https://www.businesswire.com/news/home/20231024340802/en/
    SCHOTT continues to advance pharma glass tubing.
  • The global launch of our improved borosilicate glass tubing is a first step.
  • In China, SCHOTT has been piloting and successfully established the new glass tubing for the last two years together with its customers.

PharmaJet, Nigeria’s National Primary Health Care Development Agency, and Health-focused Consortium Begin Implementation of Study Using Tropis® ID for Routine Immunization

Retrieved on: 
Tuesday, October 24, 2023
General Health, Infectious Diseases, Health, Pharmaceutical, Medical Supplies, Vaccine hesitancy, Government, Policy, Peritonitis, International development, Vaccine, Polio, Global Polio Eradication Initiative, Use, Injection, Multimedia, Criticism of the United States government, USAID, IPV, Syringe, Jhpiego, Immunization, United, PATH

Partners are also evaluating the acceptability and feasibility of using needle-free from the healthcare worker and caregiver perspective.

Key Points: 
  • Partners are also evaluating the acceptability and feasibility of using needle-free from the healthcare worker and caregiver perspective.
  • View the full release here: https://www.businesswire.com/news/home/20231024060890/en/
    Nigerian baby receiving polio vaccine with the PharmaJet Tropis® Precision Needle-free System.
  • Evidence from the study is intended to inform policy regarding intradermal delivery of polio vaccine in routine immunization settings.
  • Study preparation included the development of standard operating procedures to ensure congruence with the country’s existing medical guidelines.

Global Syringes & Needles Market Soars with a Strong 7.93% CAGR, Expected to Reach $47.20 Billion by 2029 - ResearchAndMarkets.com

Retrieved on: 
Friday, October 20, 2023
Medical Supplies, Health, Ageing, Cardinal Health, Prevalence, Conditional sentence, Diabetes, BD, Syringe, Injury, Growth, Hospital, Needle, Beauty salon, Dentistry

The global syringes & needles market is experiencing robust growth, with a projected CAGR of 7.93% from 2023 to 2029.

Key Points: 
  • The global syringes & needles market is experiencing robust growth, with a projected CAGR of 7.93% from 2023 to 2029.
  • The market, valued at $29.85 billion in 2023, is expected to reach $47.20 billion by 2029.
  • Several key factors are driving this growth, while the market is also influenced by regional dynamics and market segmentation.
  • Leading players dominating the global syringes & needles market include BD, Cardinal Health, B Braun, Nipro, and Terumo Corp.

Aldena Therapeutics Selects PCI Pharma Services to Manufacture and Distribute Innovative Investigational Treatment for Dermatological Diseases

Retrieved on: 
Thursday, October 19, 2023
Biotechnology, Pharmaceutical, Other Manufacturing, Health, Supply Chain Management, Manufacturing, Clinical Trials, Retail, III, CDMO, Research, Disease, Clinical trial, Disorder, PCI, Syringe, Therapy, Patient, Doctor of Philosophy, Automation, Pharmaceutical industry, Aldena Windham Davis Smith

Aldena Therapeutics, a private biotech company pioneering siRNA- based therapies for dermatological indications, has chosen PCI Pharma Services (PCI) , a world-leading global contract development and manufacturing organization (CDMO) to formulate, package, and distribute ALD-102, an siRNA-based investigational injectable treatment for inflammatory dermatological conditions, all under one roof at PCI’s San Diego facility.

Key Points: 
  • Aldena Therapeutics, a private biotech company pioneering siRNA- based therapies for dermatological indications, has chosen PCI Pharma Services (PCI) , a world-leading global contract development and manufacturing organization (CDMO) to formulate, package, and distribute ALD-102, an siRNA-based investigational injectable treatment for inflammatory dermatological conditions, all under one roof at PCI’s San Diego facility.
  • Dermatological diseases affect more than 900 million people worldwide.
  • Significant advancements in the treatment of various skin conditions and disorders have been made.
  • With the siRNA-based approach, Aldena develops advanced and long-lasting treatments for skin conditions.

Vaccine Journal Highlights the Potential for Self-Administration of Vaccines Using Vaxxas High-Density Microarray Patch (HD-MAP)

Retrieved on: 
Thursday, October 19, 2023
Biotechnology, Medical Devices, Infectious Diseases, Health, Pharmaceutical, Lymph, Measles, Skin, Personal protective equipment, Fever Dream, Vaccination, Immune system, COVID-19, Pharmacy, Evaluation, Biodegradable waste, Rubella, Public, Needle, Cancer, Syringe, Pharmaceutical industry, Vaccine

The publication outlines the potential for Vaxxas’ HD-MAP to enhance vaccine performance as well as increasing rates and acceptance of vaccination based on needle-free self-administration.

Key Points: 
  • The publication outlines the potential for Vaxxas’ HD-MAP to enhance vaccine performance as well as increasing rates and acceptance of vaccination based on needle-free self-administration.
  • The HD-MAP, upon which vaccines are ‘printed’ and dried, also provides storage and distribution benefits due to reduced cold chain requirements generally associated with vaccines delivered by needle and syringe.
  • Vaxxas is advancing a robust pipeline of pre-clinical and clinical stage HD-MAP vaccine candidates and has recently concluded multiple Phase I clinical studies.
  • The current Vaxxas pipeline targets COVID-19, seasonal and pandemic influenza, typhoid, measles and rubella, and cancer.

Trulieve Opening Medical Cannabis Dispensary in Apollo Beach, Florida

Retrieved on: 
Friday, October 20, 2023
Alchemy, Love, OTCQX, Cannabis, Health, CSE, Capsule, Music, Trekker, Syringe, Patient, Veteran, Drug

TALLAHASSEE, Fla., Oct. 20, 2023 /PRNewswire/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States, today announced the opening of a new medical dispensary located at 6586 N U.S. Highway 41 in Apollo Beach, Florida.

Key Points: 
  • TALLAHASSEE, Fla., Oct. 20, 2023 /PRNewswire/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States, today announced the opening of a new medical dispensary located at 6586 N U.S. Highway 41 in Apollo Beach, Florida.
  • Joining nearby Tampa Bay Trulieve locations in Tampa, St. Petersburg and Bradenton, the new Apollo Beach dispensary offers more convenience to patients along the Interstate-75 corridor in southern Hillsborough and northern Manatee counties.
  • Trulieve will host a grand opening celebration at the new Apollo Beach location beginning at 9 a.m., Saturday, October 21, with partner giveaways, music, specials, discounts, and opportunities to register for upcoming patient education sessions.
  • The new Apollo Beach dispensary will be open 9 a.m. – 8:30 p.m. Monday through Saturday and 11 a.m. – 8 p.m. on Sundays.